Instituto do Câncer do Estado de São Paulo - Academic Profile

Publications

View All

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst , Paul Baas , Dong‐Wan Kim +16 more

2015 The Lancet 6378 citations

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

2019 The Lancet 2928 citations

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz , Chiun‐Sheng Huang , Max S. Mano +26 more

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer...

2018 New England Journal of Medicine 2430 citations

Affiliated Researchers

Institution Info

Type: healthcare
Country: BR
Publications: 4
Citations: 14,911

External Links

Identifiers

ROR: https://ror.org/005vqqr19